In T-cell acute lymphoblastic leukaemia (T-ALL), increased levels of NRF2 were observed in patients classified as therapy-resistant, according to their positivity in minimal residual disease (MRD), but expression levels largely overlapped between the groups, suggesting that the use of NRF2 levels as a prognostic biomarker in this context would be challenging [7]. This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.